1,3-bis(4-isobutylphenyl)butan-1-one

Catalog No. :
ACDQWX956
CAS No. :
2143535-25-3
Molecular Formula :
C24H32O
Molecular Weight :
336.52

IUPAC Name:1,3-bis(4-isobutylphenyl)butan-1-one

1,3-bis(4-isobutylphenyl)butan-1-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1,3-bis(4-isobutylphenyl)butan-1-one
IUPAC Name1,3-bis(4-isobutylphenyl)butan-1-one
Molecular FormulaC24H32O
Molecular Weight336.52
SMILESCC(C)CC1=CC=C(C(=O)CC(C)C2=CC=C(CC(C)C)C=C2)C=C1
InChI KeyQJBUYPFVSVNYDO-UHFFFAOYSA-N
SynonymIbuprofen IMP;Ibuprofen impurity 3/Ibuprofen EP Impurity H/2-[4-(2-Methylpropyl)phenyl] ethanol;Ibuprofen EP Impurity H:Ibuprofen Impurity H;Ibuprofen Impurity 8(Ibuprofen EP Impurity H);Ibuprofen EP Impurity HQ: What is Ibuprofen EP Impurity H Q: What is the CAS Number of Ibuprofen EP Impurity H;Ibuprofen EP Impurity HQ: What is Ibuprofen EP Impurity H Q: What is the CAS Number of Ibuprofen EP Impurity H Q: What is the storage condition of Ibuprofen EP Impurity H Q: What are the applications of Ibuprofen EP Impurity H;1,3-Bis(4-isobutylphenyl)butan-1-one (Ibuprofen Impurity);2-[4-(2-Methylpropyl)phenyl] ethanol
CAS No.2143535-25-3

Synthetic Route by SureRoute

1. ACDQWX956 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACIQAN650 route compound structure diagram
    ACIQAN6502051-99-2 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACDQWX956 route product structure diagram
    ACDQWX9562143535-25-3
Inquiry

2. ACDQWX956 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACDQWX956 route product structure diagram
    ACDQWX9562143535-25-3
Inquiry

Comments (0)